Skip to main content

futibatinib

Generic: FUTIBATINIB·Brand: LYTGOBI, Lytgobi

futibatinib: 7 clinical trials tracked.

futibatinib evidence translation

What we can confirm

7 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about futibatinib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 2 study sponsors
Clinical Trials (7)

An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study

NCT06506955·Phase 2/Phase 3·CGON
Active, not recruiting

Primary endpoint: Number of participants with serious adverse events, treatment-related adverse events, and any AEs leading to treatment discontinuation graded according to NCI-CTCAE v5.0.

Interventionalopen15 targetStarted 2024-10Completion 2027-049 sites · France, South Korea, Spain, United Kingdom…Taiho Oncology, Inc.

Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial

NCT05615818·Phase 3
Recruiting

Primary endpoint: Progression-free survival (PFS)

InterventionalRandomizedopen800 targetStarted 2024-07Completion 2028-0650 sites · Belgium, France, United KingdomUNICANCER

An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications

NCT05827614·Phase 1·BOLD
Terminated

Primary endpoint: Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-355 as a single agent and in combination with each of the following agents: erlotinib, futibatinib, or BBI-825

Interventionalopen85 enrolledStarted 2023-03Completion 2026-0316 sites · United StatesBoundless Bio, Inc.

A Phase 2 Study Evaluating Futibatinib (TAS 120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma

NCT04601857·Phase 2·CGON
Terminated

Primary endpoint: Objective Response Rate (ORR)

Interventionalopen43 targetStarted 2021-01Completion 2025-0918 sites · France, Spain, United StatesTaiho Oncology, Inc.

A Phase 2 Study of Futibatinib in Patients With Specific FGFR Aberrations

NCT04189445·Phase 2·CGON
Terminated

Primary endpoint: Objective Response Rate (ORR) Based on Independent Central Review (IRC) in Cohorts A and B

Interventionalopen115 targetStarted 2020-08Completion 2024-1150 sites · Belgium, France, Germany, Hong Kong…Taiho Oncology, Inc.

A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications

NCT04024436·Phase 2·CGON
Terminated

Primary endpoint: Objective Response Rate (ORR) - Cohorts 1, 2

Interventionalopen64 targetStarted 2020-01Completion 2023-0937 sites · Canada, France, Italy, Portugal…Taiho Oncology, Inc.

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

NCT02693535·Phase 2·CGON
Recruiting

Primary endpoint: Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria

Interventionalopen4,200 targetStarted 2016-03Completion 2028-1250 sites · United StatesAmerican Society of Clinical Oncology